Detalhe da pesquisa
1.
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
N Engl J Med
; 386(12): 1132-1142, 2022 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35179323
2.
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
N Engl J Med
; 384(14): 1289-1300, 2021 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33616314
3.
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
Lancet Oncol
; 24(3): 228-238, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36858721
4.
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
N Engl J Med
; 383(13): 1218-1230, 2020 09 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-32945632
5.
Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).
J Urol
; 210(4): 619-629, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37548555
6.
Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer.
Future Oncol
; 18(19): 2361-2371, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35416053
7.
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet Oncol
; 16(4): 417-25, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25743937
8.
A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer.
Eur J Cancer
; 202: 114007, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38518534
9.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
J Clin Oncol
; 42(11): 1222-1228, 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38227898
10.
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.
J Clin Oncol
; 41(20): 3595-3607, 2023 07 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36795843
11.
Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study.
Eur Urol Oncol
; 6(4): 437-446, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36720658
12.
Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma.
Eur Urol
; 83(4): 320-328, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35654659
13.
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.
Front Oncol
; 13: 1223282, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37664025
14.
Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.
Front Oncol
; 13: 1343027, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38495081
15.
Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial.
Eur Urol
; 79(3): 334-338, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33461782
16.
Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.
JAMA Oncol
; 3(7): 913-920, 2017 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27787547
17.
Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study.
JAMA Oncol
; 3(1): 68-75, 2017 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27560549
18.
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.
J Clin Oncol
; 35(35): 3916-3923, 2017 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28902533